International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis(Memorial Sloan Kettering Cancer Center), David Yankelewitz, Pan‐Chyr Yang(Institute of Biomedical Sciences, Academia Sinica), Bruce Johnson(Mayo Clinic), Charles A. Powell(Icahn School of Medicine at Mount Sinai), Yuichi Ishikawa(Sasaki Institute), Élisabeth Brambilla(Centre National de la Recherche Scientifique), David Johnson(Prince of Wales Hospital), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Masahiro Tsuboi(National Cancer Center Hospital East), Kavita Garg, Masayuki Noguchi(University of Tsukuba), Valerie W. Rusch(Memorial Sloan Kettering Cancer Center), David G. Beer(University of Michigan–Ann Arbor), Kim R. Geisinger(East Carolina University), Adi F. Gazdar(Weatherford College), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Hisao Asamura(Keio University), Yasushi Yatabe(University Hospital Münster), Denise R. Aberle, Fred R. Hirsch(Tisch Hospital), Ming‐Sound Tsao(Kumamoto University), Michael K. Gould(Kaiser Permanente), Erik Thunnissen(Amsterdam University Medical Centers), Montse Sánchez‐Céspedes(Josep Carreras Leukaemia Research Institute), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Tetsuya Mitsudomi(Kindai University), Christian Brambilla(Inserm), Andrew G. Nicholson(Guy's and St Thomas' NHS Foundation Trust), Takashi Takahashi(Aichi Cancer Center), Victor L. Roggli(Duke Medical Center), Keiko Kuriyama, Jin Soo Lee(Ajou University), Iver Petersen(SRH Wald-Klinikum Gera), Douglas W. Henderson(Flinders Medical Centre), Johan Vansteenkiste, P S Hasleton(University of Manchester), Wilbur A. Franklin(University of Colorado Health), James R. Jett(Pulmonary and Critical Care Associates), Rafael Rosell(Instituto Oncológico Dr. Rosell), Jean‐Paul Sculier, Vincent A. Miller(Universidad San Carlos), Nagahiro Saijo(National Cancer Center Hospital East), Keith M. Kerr(University of Aberdeen), Paul E. Van Schil(Antwerp University Hospital), Douglas B. Flieder, John H. M. Austin, Rudolf M. Huber(Clinica de Pneumologie Iaşi)
Cited by 4,838
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k